Beta Bionics targets Q2 2027 commercialization for Mint patch pump

Beta Bionics, Inc.

Expects full commercialization of Mint patch pump by end of Q2 2027, subject to FDA clearance.
Timeline based on FDA initial responses to 510(k) ACE insulin pump application and manufacturing scale progress.
Mint features: 200-unit reservoir, 3-day wear, waterproof, smartphone controlled, no recharging needed.
Compatible with Beta Bionics' iAGC algorithm and Dexcom G7, Abbott FreeStyle Libre 3 Plus CGMs.
Exclusively available in pharmacy channel; manufacturing capacity expected to meet launch demand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.